RT Journal Article
SR Electronic
T1 The Effect of <sup>131</sup>I Therapy on the Eradication of <em>Helicobacter pylori</em> in Patients with Thyroid Disorders: A Preliminary Study
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 144
OP 147
DO 10.2967/jnmt.123.266508
VO 52
IS 2
A1 Pourfarzi, Farhad
A1 Pakrouy, Hossein
A1 Mohammadian Erdi, Ali
A1 Faghfuri, Elnaz
YR 2024
UL http://tech.snmjournals.org/content/52/2/144.abstract
AB The leading cause of gastritis and its complications is Helicobacter pylori. Radioactive iodine (131I) accumulates significantly in the stomach after consumption. On this basis, we decided to determine whether different doses of 131I in the stomach would be effective in eradicating the infection. Methods: All patients with hyperthyroidism or differentiated thyroid carcinoma who were referred for 131I treatment were invited to the study. A stool antigen test was conducted before consumption of 131I (0.15–5.5 GBq) and was repeated 2 mo later to detect H. pylori infection. Results: H. pylori positivity was found in 51.8% (14/27) of the patients. At 2 mo after treatment, 13 of the 14 patients with differentiated thyroid carcinoma or hyperthyroidism who had been identified as positive for H. pylori stool antigen before 131I administration were still positive, representing a nonsignificant eradication rate of 7.1%. Conclusion: Administration of 131I to patients with H. pylori did not show potential to eliminate the infection.